{
    "organizations": [],
    "uuid": "22aa80e93f4d6ed4cdc8d63f00a6ba8c91605320",
    "author": "",
    "url": "https://www.reuters.com/article/brief-xencor-doses-first-patient-in-phas/brief-xencor-doses-first-patient-in-phase-1-study-of-xmab18087an-antibody-for-treatment-of-neuroendocrine-tumors-and-gastrointestinal-stromal-tumors-idUSFWN1QC0Y5",
    "ord_in_thread": 0,
    "title": "BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News February 22, 2018 / 1:11 PM / Updated 3 minutes ago BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors Reuters Staff 1 Min Read Feb 22 (Reuters) - Xencor Inc: * XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS * XENCOR INC SAYS “EXPECTS TO FILE INDS FOR 3 MORE BISPECIFIC ANTIBODIES FOR SOLID TUMORS THIS YEAR” Source text for Eikon: Further company coverage:",
    "published": "2018-02-22T15:10:00.000+02:00",
    "crawled": "2018-02-22T15:18:26.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "dos",
        "first",
        "patient",
        "phase",
        "study",
        "antibody",
        "treatment",
        "neuroendocrine",
        "tumor",
        "gastrointestinal",
        "stromal",
        "tumor",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "xencor",
        "inc",
        "xencor",
        "dos",
        "first",
        "patient",
        "phase",
        "study",
        "bispecific",
        "tumor",
        "targeting",
        "antibody",
        "treatment",
        "neuroendocrine",
        "tumor",
        "gastrointestinal",
        "stromal",
        "tumor",
        "xencor",
        "inc",
        "say",
        "expects",
        "file",
        "inds",
        "bispecific",
        "antibody",
        "solid",
        "tumor",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}